P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 17.2 CNY -5.29% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Porton Pharma Solutions Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Porton Pharma Solutions Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Net Income (Common)
-ÂĄ391.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.5B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.4B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd. engages in the research and development and manufacture of pharmaceutical products and active pharmaceutical ingredients. The company is headquartered in Chongqing, Chongqing and currently employs 3,782 full-time employees. The company went IPO on 2014-01-29. The firm is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The firm operates its businesses in Europe, North America, Asia and China, among others.

Intrinsic Value
20.26 CNY
Undervaluation 15%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Net Income (Common)?
Net Income (Common)
-391.4m CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Net Income (Common) amounts to -391.4m CNY.

Back to Top